The hottest Proteomics Substack posts right now

Ultima Genomics has won a significant project with the UK Biobank to analyze 700,000 samples. This partnership is a major step for them in the field of proteomics.
Despite the project size, Ultima is expected to generate only $10 million to $20 million in revenue. This highlights the tough financial realities in the biotech industry.
To stay viable, Ultima needs to secure more large projects, as its costs are high. Achieving the necessary volume of work may be challenging given the current economic situation.

Researchers developed a new tool called SLiPP that helps quickly find proteins that interact with lipids. This is important because lipids play key roles in cell functions and diseases.
SLiPP uses machine learning to distinguish between protein pockets likely to bind lipids and those that won't. This makes it easier to identify potential targets for drug discovery.
The tool has been successfully tested on different organisms, showing it can accurately predict lipid-binding proteins. This helps scientists explore new areas in lipid biology and disease research.

A new method is developed for predicting protein functions using something called conformal prediction. This makes the predictions more reliable and provides a clear way to understand risks when selecting proteins.
The approach helps in annotating genes and predicting enzyme functions more accurately without needing new training models. This is great for speeding up research in life sciences.
It also offers a smart way to reduce the number of proteins needing full analysis, making the process quicker and cheaper while still keeping good accuracy.

A new method helps find powerful compounds that can target hard-to-reach proteins for drug development. These compounds are called molecular glue degraders, and they can help break down unwanted proteins in the body.
The study found many new targets for these compounds, including some that haven't been studied much before. This expands the potential for developing new treatments for diseases like cancer.
The researchers created a process that combines different scientific techniques, making it easier to design and improve these drugs. This means we might see more precise and effective medicines in the future.

Over 30 million people in the US are affected by kidney disease, leading to high healthcare costs and lowered quality of life.
New tools like genomics, proteomics, and metabolomics are transforming drug development for kidney diseases.
Companies like Goldfinch Bio and Chinook Therapeutics are developing medicines for rare kidney diseases with defined clinical milestones.

Get a weekly roundup of the best Substack posts, by hacker news affinity:

Protein sequencing can potentially be easier than expected with nanopore technology, allowing for detection of PTMs and obtaining unique fingerprints from proteins.
Proteomics differs from DNA sequencing in that it allows for estimating protein abundance and identifying PTMs in samples, possibly through aligning multiple protein traces.
Challenges in proteomics applications with nanopore platforms include achieving the necessary dynamic range for accurate measurements, which may require advancements in technology.

Kidney disease affects over 30 million people in the US with high healthcare costs.
New tools like genomics, proteomics, and metabolomics show promise in understanding kidney biology and drug development.
CKD is a big opportunity for new treatments, focusing on new MoAs like loss of podocytes, chemokines, JAK inhibitors, and ECM deposition.